Biotechnology Center, School of Life Science and Technology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.
Appl Microbiol Biotechnol. 2012 Sep;95(6):1437-44. doi: 10.1007/s00253-012-4122-0. Epub 2012 May 10.
Epitope vaccine based on the enzyme urease of Helicobacter pylori is a promising option for prophylactic and therapeutic vaccination against H. pylori infection. In our previous study, the epitope vaccine CTB-UA, which was composed of the mucosal adjuvant cholera toxin B subunit (CTB) and an epitope (UreA₁₈₃₋₂₀₃) from the H. pylori urease A subunit (UreA) was constructed. This particular vaccine was shown to have good immunogenicity and immunoreactivity and could induce specific neutralizing antibodies, which exhibited effectively inhibitory effects on the enzymatic activity of H. pylori urease. In this study, the prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA was evaluated in a BALB/c mice model. The experimental results indicated that oral prophylactic or therapeutic immunization with CTB-UA significantly decreased H. pylori colonization compared with oral immunization with PBS. The results also revealed that the protection was correlated with antigen-specific IgG, IgA, and mucosal secretory IgA antibody responses. CTB-UA may be a promising vaccine candidate for the control of H. pylori infection.
基于幽门螺杆菌酶尿素酶的表位疫苗是预防和治疗幽门螺杆菌感染的有前途的选择。在我们之前的研究中，构建了由黏膜佐剂霍乱毒素 B 亚单位（CTB）和幽门螺杆菌尿素酶 A 亚单位（UreA）的一个表位（UreA₁₈₃₋₂₀₃）组成的表位疫苗 CTB-UA。该特定疫苗具有良好的免疫原性和免疫反应性，可诱导特异性中和抗体，对幽门螺杆菌尿素酶的酶活性表现出有效的抑制作用。在这项研究中，在 BALB/c 小鼠模型中评估了表位疫苗 CTB-UA 的预防和治疗功效。实验结果表明，与口服 PBS 免疫相比，口服预防性或治疗性 CTB-UA 免疫可显著降低幽门螺杆菌定植。结果还表明，保护与抗原特异性 IgG、IgA 和黏膜分泌型 IgA 抗体反应相关。CTB-UA 可能是控制幽门螺杆菌感染的有前途的疫苗候选物。
